Researchers say they created a 10-minute universal cancer test, but experts remain skeptical

This post was originally published on this site

A group of researchers claim to have created a “breakthrough” blood test that could identify the presence of cancer. While such a test sounds promising, it’s not necessarily foolproof, experts cautioned.

When analyzing healthy cells and cancer cells, scientists at the University of Queensland in Australia found cancer DNA fragments adhered to solid surfaces such as metals in very different ways. Using that information, they developed a “simple” test where blood would be mixed with a solution containing gold nanoparticles, according to an article they published in Nature Communications, a peer-reviewed, open access scientific journal. If cancerous DNA of any kind is present in the blood, the gold nanoparticles change color.

“Discovering that cancerous DNA molecules formed entirely different 3D nanostructures from normal circulating DNA was a breakthrough that has enabled an entirely new approach to detect cancer non-invasively in any tissue type including blood,” said Matt Trau, a professor at the University of Queensland and one of the study’s co-authors, in a statement.

Also see: Kentucky congressman questions food stamps: ‘If healthcare is a right, is food as well?’

The researchers argued that their test could pave the way for a cheaper, faster cancer diagnosis process. The testing process only takes 10 minutes and can be adapted to occur within an inexpensive and portable diagnosis device, they said. “We certainly don’t know yet whether it’s the holy grail for all cancer diagnostics, but it looks really interesting as an incredibly simple universal marker of cancer, and as an accessible and inexpensive technology that doesn’t require complicated lab-based equipment like DNA sequencing,” Trau said.

Observers though were most hesitant in celebrating the news. Indeed, this is just the latest example of a “simple” cancer blood test. Back in June, a separate group of researchers from the U.S. announced they had created a blood test that could identify as many as 10 types of cancer. And in January, scientists from the Johns Hopkins School of Medicine announced the formulation of a $500 blood test called CancerSEEK, which could identify eight types of cancer before symptoms developed.

“I have often said that anytime you hear about a ‘simple cancer test,’ run for the hills because there’s no such thing,” Gary Schwitzer, founder and publisher of, wrote in an article advising caution regarding the latest cancer blood test. “This researcher may be referring to the technology, but the application of that technology — the leap from lab to bedside — brings with it many levels of complexity.”

In particular, the Australian researchers noted that their test successfully identified 90% of cancer cases, but as Schwitzer noted “the claim of an incredibly simple universal marker starts to sound a bit hollow” for those whose cancer wasn’t identified by the test.

Moreover, while the test allegedly can identify if someone has cancer to begin with, it cannot yet determine the origin or severity of the disease. For that, patients would need to go through additional testing, which takes time and can create anxiety.

Others expressed concern about whether the test could produce false positives, which could force people to go through unnecessary testing and stress.

Get a daily roundup of the top reads in personal finance delivered to your inbox. Subscribe to MarketWatch's free Personal Finance Daily newsletter. Sign up here.

More from MarketWatch
Be Sociable, Share!

Related Posts


MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.

This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.

The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The educational training program and software services are provided to improve financial understanding.

The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.